Triple Negative Breast Cancer in an Appalachian Region
Exponential Tumor Grade Increase with Age of Diagnosis

Gina Sizemore, PhD

Toni Marie Rudisill, PhD, MS

West Virginia University

Recommended Citation:

Sizemore G, Rudisill TM. Triple Negative Breast Cancer in an Appalachian Region: Exponential Tumor Grade Increase with Age of Diagnosis. J Appalach Health 2021;3(3):97–109. DOI: https://doi.org/10.13023/jah.0303.08.

Copyright © 2021 Gina Sizemore and Toni Rudisill
**ABSTRACT**

**Introduction:** Triple negative breast cancer is an aggressive breast cancer with decreased five-year survival, increased risk for recurrence, and higher risk for metastases. Unlike other breast cancers, it has no targeted treatment and has heterogenous genetics which make classification and treatment difficult.

**Purpose:** The purpose of our research was to compare triple negative breast cancer to non-triple negative breast cancer to identify key epidemiologic factors that might lead to improved basic science directives for biomarkers, treatments, and classification.

**Methods:** The state cancer registry was used to provide the first West Virginia statewide population evaluation of triple negative breast cancer.

**Results:** The research reveals novel results that tumor grade increases exponentially with the age at diagnosis.

**Implications:** This creates an epidemiologic foundation for future research to define whether the disease, access to care, biology of aging, or some other factor cause this significant finding. In addition, results reveal decreased use of testing that could be increased to improve biomarker identification, targeted treatments, and classification of triple negative breast cancer.

Keywords
Appalachia, disease biology, breast cancer testing, genetics, tumor classification
INTRODUCTION

Worldwide, breast cancer is a leading cause of cancer mortality in women\(^1\) and in the U.S., invasive breast cancer impacts 12.4% of the population of women.\(^2\) Breast cancer is a diverse disease with five molecular subtypes. One type is triple negative breast cancer (TNBC), a breast cancer where tumors are negative for estrogen receptor, progesterone receptor, and Human Epidermal Growth Factor Receptor 2 overexpression.\(^3,4\) Because of its heterogeneity, TNBC is further divided into sub-types whose classification is still controversial with the most recent being the genetic profile classification.\(^5\) TNBC is an aggressive disease and is associated with a poorer prognosis and 5-year survival rate as there is a higher risk for recurrence and metastasis among affected patients.\(^6–8\) Previous studies have shown that the prevalence of TNBC is higher in some demographic groups such as women under 40 years of age and among women of black race or Hispanic ethnicity.\(^6,7,9–14\)

The reasons why certain demographic groups are more affected than others are unknown. Previous studies have proposed that obesity, diet, genetics, socioeconomic, and biological factors may explain differences seen among demographic groups in terms of TNBC.\(^3,6–8,11,15,16\)

Because of the severity of TNBC, there has been an increased interest in investigating demographic, diagnostic, and prognostic factors associated with the disease not only nationwide, but also in West Virginia.\(^8,9,17\) The age-adjusted breast cancer mortality rate among women in West Virginia is the 8th highest among states.\(^18\) In addition to the high mortality rate, West Virginia’s population is somewhat homogenous compared to other states as over 94% of the population is non-Hispanic white\(^19\); thus, racial differences may be observed to a lesser extent. However, the population is of lower socioeconomic status and has greater levels of obesity compared to most other states.\(^20,21\) The state also has a low net migration of residents which could indicate that hereditary factors associated with TNBC, such as BRCA mutations, may remain present in the population and influence the disease’s prevalence.\(^3,22\)

To date, two studies have investigated TNBC in West Virginia.\(^8,17\) One study found that West Virginia patients had increased representation of advanced tumors at time of diagnosis.\(^17\) The other study determined that a greater proportion of women with TNBC were under the age of 50 and that their tumors were larger than non-TNBC patients; TNBC patients also were slightly more obese than non-TNBC patients.\(^8\) However, both studies utilized unique patient populations from a university hospital and/or a regional medical center over 15 years ago. Thus, the purpose of this study was to investigate the demographic and diagnostic differences between those diagnosed with TNBC compared to non-TNBC utilizing more recent data from the state’s cancer registry, which includes all patients diagnosed with breast cancer in the state. The findings of this study could help inform future research in a state where cancer risk and mortality are high.
METHODS

Data Source

The primary data source for this analysis was the West Virginia Cancer Registry, which is maintained by the West Virginia Department of Health and Human Resources in Charleston, WV. Since 1993, the registry maintains demographic and clinical data on individuals who are diagnosed and treated for cancer within the state. The registry also includes West Virginia residents who were treated outside the state boundary but retain a West Virginia address. The registry collects, codes, and maintains these data in accordance with the National Cancer Institute’s Surveillance, Epidemiology and End Results Program (SEER). The data are de-identified for patient confidentiality purposes.

Study Population

The study population included all West Virginia women who were diagnosed with breast cancer (e.g., International Classification of Diseases for Oncology, Third Edition, codes C500–C509) from January 1, 2010, thru December 31, 2016. The data years 2010–2016 were selected because there were data quality concerns prior to 2010 and 2016 was the most recent data year available.

Human Subject’s Protections

This study was approved by West Virginia University’s Institutional Review Board (protocol #1908679407).

Variables

The primary dependent variable was whether an individual was diagnosed with TNBC (e.g., dichotomous). TNBC was defined in accordance to SEER as a breast cancer that is negative for estrogen receptors, progesterone receptors, and Human Epidermal Growth Factor Receptor 2 overexpression. Various independent variables were utilized for this analysis which included: patient’s age at diagnosis, race, year of diagnosis, stage of cancer at diagnosis, whether their cancer metastasized (binary), whether the patient’s ipsilateral axillary lymph nodes were implicated (binary), whether the cancer was entirely in situ (binary), tumor grade, whether a multigene test was performed on the patient (binary), and whether the patient was diagnosed with Paget’s disease of the breast (binary). The categorization of these variables is shown in Table 1. Race was dichotomized into white or other due the demographics of the state (e.g., it is primarily non-Hispanic white). For tumor grade, some patients were given a Bloom-Richardson score. Those with scores 3–5 were considered low grade. Those with scores 6–7 or 8–9 were categorized as moderate and high grade, respectively.
| Characteristic                  | TNBC | %   | Non-TNBC | %   | Total | %   |
|--------------------------------|------|-----|----------|-----|-------|-----|
| **Age group**                  |      |     |          |     |       |     |
| ≤40                            | 81   | 7.0 | 318      | 4.0 | 399   | 4.4 |
| 41–50                          | 205  | 17.6| 1055     | 13.3| 1260  | 13.9|
| 51–60                          | 290  | 24.9| 1832     | 23.1| 2122  | 23.3|
| 61–70                          | 317  | 27.2| 2326     | 29.3| 2643  | 29.0|
| ≥71                            | 273  | 23.4| 2403     | 30.3| 2676  | 29.4|
| Missing                        | 0    |     | 0        |     | 0     |     |
| **Race**                       |      |     |          |     |       |     |
| White                          | 1098 | 94.2| 7665     | 96.7| 8763  | 96.3|
| Other                          | 68   | 5.8 | 264      | 3.3 | 332   | 3.7 |
| **Year of diagnosis**          |      |     |          |     |       |     |
| 2010                           | 167  | 14.3| 979      | 12.3| 1146  | 12.6|
| 2011                           | 171  | 14.7| 1052     | 13.3| 1223  | 13.4|
| 2012                           | 161  | 13.8| 1138     | 14.3| 1299  | 14.3|
| 2013                           | 172  | 14.8| 1172     | 14.8| 1344  | 14.8|
| 2014                           | 151  | 13.0| 1166     | 14.7| 1317  | 14.5|
| 2015                           | 185  | 15.9| 1197     | 15.1| 1382  | 15.2|
| 2016                           | 159  | 13.6| 1230     | 15.5| 1389  | 15.3|
| **Stage at diagnosis**         |      |     |          |     |       |     |
| Local                          | 734  | 63.4| 5258     | 66.7| 5992  | 66.2|
| Regional direct                | 26   | 2.3 | 151      | 1.9 | 177   | 2.0 |
| Regional lymph                 | 255  | 22.0| 1817     | 23.0| 2072  | 22.9|
| Direct and lymph               | 49   | 4.2 | 214      | 2.7 | 263   | 2.9 |
| Distant                        | 94   | 8.1 | 448      | 5.7 | 542   | 6.0 |
| Unknown                        | 8    |     | 46       |     | 54    |     |
| Metastasis                     |      |     |          |     |       |     |
| Yes                            | 73   | 6.9 | 389      | 5.4 | 7867  | 94.5|
| No                             | 993  | 93.1| 6874     | 94.6| 462   | 5.6 |
| Missing                        | 100  |     | 671      |     | 771   |     |
| **Node involvement**           |      |     |          |     |       |     |
| Yes                            | 283  | 29.8| 1985     | 29.6| 2268  | 29.6|
| No                             | 668  | 70.2| 4730     | 70.4| 5398  | 70.4|
| Missing                        | 215  |     | 1219     |     | 1434  |     |
| **In situ**                    |      |     |          |     |       |     |
| Yes                            | 3    | 0.3 | 15       | 0.2 | 18    | 0.2 |
| No                             | 1093 | 99.7| 7599     | 99.8| 8692  | 99.8|
| Missing                        | 70   |     | 320      |     | 390   |     |
| **Tumor grade**                |      |     |          |     |       |     |
| Low                            | 60   | 5.6 | 2164     | 29.2| 2224  | 26.3|
| Moderate                       | 226  | 21.3| 3571     | 48.2| 3797  | 44.8|
| High                           | 777  | 73.1| 1670     | 22.6| 2447  | 28.9|
| Missing                        | 103  |     | 529      |     | 632   |     |
| **Multigene test performed**   |      |     |          |     |       |     |
| Yes                            | 49   | 5.8 | 1759     | 28.8| 1808  | 26.0|
| No                             | 802  | 94.2| 4346     | 71.2| 5148  | 74.0|
| Missing                        | 315  |     | 1829     |     |       |     |
| **Paget's**                    |      |     |          |     |       |     |
| Yes                            | 6    | 0.7 | 62       | 1.0 | 68    | 1.0 |
| No                             | 900  | 99.3| 5960     | 99.0| 6860  | 99.0|
| Missing                        | 260  |     | 1912     |     | 2172  |     |
ANALYSES

Because the objective of this study was to compare the characteristics of women in West Virginia who were diagnosed with TNBC to other types of breast cancers, several analyses were conducted. The demographic and diagnostic characteristics between those diagnosed with and without TNBC were compared via frequencies and percentages. In order to determine which variables were associated with TNBC in patients, both binary and multivariable logistic regression analyses were conducted; these types of models were chosen because the outcome was dichotomous. Unadjusted (i.e., binary) models were ran between each independent variable and the outcome. All multivariable models were adjusted for age group, race, and year of diagnosis. (However, it should be noted that the multivariable model for age group was only adjusted for year and race and the multivariable model for race was only adjusted for year and age group). These models were adjusted for these variables because there are known differences with TNBC diagnoses among different age groups and races in other clinical populations. Year was also adjusted for because of the increasing awareness of TNBC in the literature overtime which could potentially influence diagnoses. A third set of multivariable models were ran to investigate potential effect measure modification. These models contained the same variables in the first multivariable model but also included two interaction terms; there was one interaction term between the independent variable of interest and age group and another interaction term between the independent variable of interest and race. All data management and statistical analyses were conducted in SAS/STAT software version 9.4 (Cary, NC) with two-sided significance level α=0.05.

RESULTS

Nearly 13% of the women diagnosed with breast cancer in West Virginia had TNBC (Table 1). While nearly 60% of all breast cancer patients were over 60 years of age, a slightly larger proportion of women ≤40 years of age were diagnosed with TNBC (7%) compared to those with non-TNBC (4%). In regard to race, there was an increased percentage of non-whites (6%) diagnosed with TNBC compared to the non-TNBC group (3%). The stage of cancer at diagnosis confirmed a more aggressive cancer in TNBC with (4.2%) involving direct and lymph nodes compared to non-TNBC (2.7%) and a distant cancer in TNBC (8.1%) compared to distant cancer in non-TNBC (5.7%) at time of diagnosis. Metastasis was higher in TNBC (6.9%) compared to non-TNBC (5.4%). Tumor grade differed in TNBC patients with 73.1% in high grade compared to only 22.6% high grade in non-TNBC. While only 26% of patients with breast cancer received a multigene test, only 6% of TNBC patients received it compared to 29% of non-TNBC patients.

Table 2 shows the association between TNBC and demographic and diagnostic criteria. After adjusting for race and year, the odds of TNBC diagnoses in women ≤40 was 2.2 times greater than the odds of TNBC in women ≥71 years of age. The odds of a TNBC diagnosis in non-whites was 71% higher than the odds of TNBC in whites.
after adjusting for age and year. Additionally, it appeared that TNBC was associated with higher tumor grades. The odds of TNBC was 16 times greater in high tumor grades than the odds of TNBC in women with low tumor grades at time of diagnosis after adjusting for age, race, and year. Yet, the odds of a TNBC diagnoses was 86% lower among those receiving a multigene test compared to the odds of a TNBC diagnoses among those not receiving a multigene test.

### Table 2. The association between triple negative breast cancer (TNBC) and demographic and diagnostic criteria

| Characteristic | Total N | % of population with TNBC | Model 1 | Model 2 |
|----------------|---------|---------------------------|---------|---------|
| **Age group**  |         |                           |         |         |
| ≤40            | 399     | 20.3                      | 2.24    | 1.70, 2.95 | 2.19 | 1.67, 2.88 |
| 41-50          | 1260    | 16.3                      | 1.71    | 1.41, 2.08 | 1.68 | 1.38, 2.05 |
| 51-60          | 2122    | 13.7                      | 1.39    | 1.17, 1.66 | 1.38 | 1.15, 1.64 |
| 61-70          | 2643    | 12.0                      | 1.20    | 1.01, 1.42 | 1.20 | 1.01, 1.42 |
| ≥71            | 2676    | 10.2                      | 1.00    | Referent  | 1.00 | Referent   |
| **Race**       |         |                           |         |         |
| White          | 8763    | 12.5                      | 1.00    | Referent | 1.00 | Referent   |
| Other          | 332     | 20.5                      | 1.80    | 1.38, 2.37 | 1.71 | 1.30, 2.26 |
| **Node Involvement** | | | | |
| Yes            | 2268    | 12.5                      | 1.01    | 0.87, 1.17 | 0.95 | 0.81, 1.10 |
| No             | 5398    | 12.4                      | 1.00    | Referent  | 1.00 | Referent   |
| **In situ**    |         |                           |         |         |
| Yes            | 18      | 16.7                      | 1.39    | 0.40, 4.81 | 1.58 | 0.46, 5.49 |
| No             | 8692    | 12.6                      | 1.00    | Referent  | 1.00 | Referent   |
| **Tumor grade**|         |                           |         |         |
| Low            | 2224    | 2.7                       | 1.00    | Referent  | 1.00 | Referent   |
| Moderate       | 3797    | 6.0                       | 2.28    | 1.71, 3.05 | 2.27 | 1.70, 3.03 |
| High           | 2447    | 31.8                      | 16.78   | 12.81, 21.98 | 16.24 | 12.38, 21.30 |
| **Metastasis** |         |                           |         |         |
| Yes            | 462     | 15.8                      | 1.30    | 1.00, 1.68 | 1.29 | 0.99, 1.67 |
| No             | 7867    | 12.6                      | 1.00    | Referent  | 1.00 | Referent   |
| **Multigene**  |         |                           |         |         |
| Yes            | 1808    | 2.7                       | 0.15    | 0.11, 0.20 | 0.14 | 0.11, 0.19 |
| No             | 5148    | 15.6                      | 1.00    | Referent  | 1.00 | Referent   |
| **Paget**      |         |                           |         |         |
| Yes            | 68      | 8.8                       | 0.64    | 0.28, 1.49 | 0.66 | 0.28, 1.53 |
| No             | 6860    | 13.1                      | 1.00    | Referent  | 1.00 | Referent   |

Abbreviations: TNBC=triple negative breast cancer

Model 1 is a binary model between the characteristic and TNBC status (yes/no) as the outcome. Model 2 is the adjusted model. All adjusted models, except age group and race, were adjusted for age group, race, and year of diagnosis. The multivariable model for age group was adjusted for year and race. The multivariable model for race was adjusted for year and age group.
Age was an effect modifier of the relationship between TNBC diagnoses and tumor grade (Table 3). After adjusting for both year and race, the odds of TNBC dramatically increased with more severe tumor grades over the age groups. A female under the age of 40 diagnosed with TNBC had 5 times greater odds of having a high tumor grade compared to the odds of a woman in the same age group diagnosed with TNBC having a low-grade tumor. However, the odds of TNBC for a female ≥71 years of age to be high grade stage was nearly 22 times greater than the odds of a TNBC diagnoses for a female in the same age group having a low-grade tumor.

| Grade by Age group | OR  | 95% CI   |
|--------------------|-----|----------|
| ≤40                |     |          |
| Low                | 1.00| Referent |
| Moderate           | 1.16| 0.36, 3.73 |
| High               | 5.41| 1.85, 15.80 |
| 41-50              |     |          |
| Low                | 1.00| Referent |
| Moderate           | 1.12| 0.55, 2.27 |
| High               | 10.48| 5.67, 19.39 |
| 51-60              |     |          |
| Low                | 1.00| Referent |
| Moderate           | 1.89| 1.03, 3.46 |
| High               | 14.61| 8.37, 25.52 |
| 61-70              |     |          |
| Low                | 1.00| Referent |
| Moderate           | 2.54| 1.46, 4.42 |
| High               | 20.17| 11.96, 34.02 |
| ≥71                |     |          |
| Low                | 1.00| Referent |
| Moderate           | 3.64| 2.04, 6.50 |
| High               | 21.73| 12.42, 38.03 |

Table 3. Effect measure modification of tumor grade by age group among patients diagnosed with triple negative breast cancer vs. regular breast cancera

a: Model was adjusted for year and race. The outcome was whether the patient was diagnosed for triple negative breast cancer vs. regular breast cancer. The primary independent variable was tumor grade at diagnosis, which is stratified by age group.

Age was also an effect modifier of the relationship between TNBC diagnosis and multigene test conductance (Table 4). It appears that the conductance of the multigene test decreases with age. While there were no differences in women ≤40, after adjusting for year and race, the odds of TNBC diagnoses among those aged 41–50 years is 75% lower if multigene test is conducted compared to the odds of a TNBC diagnoses among women of the same age who do not receive the multigene signature.
test. However, the odds of TNBC diagnoses among those aged ≥71 years is 88% lower if multigene test is conducted compared to the odds of a TNBC diagnoses among women of the same age who do not receive the multigene signature test.

| Multigene test by age group | Model 1 | 95% CI |
|-----------------------------|---------|--------|
| ≤40                          |         |        |
| Yes                         | 0.52    | 0.24, 1.13 |
| No                          | 1.00    | Referent |
| 41-50                       |         |        |
| Yes                         | 0.25    | 0.15, 0.43 |
| No                          | 1.00    | Referent |
| 51-60                       |         |        |
| Yes                         | 0.05    | 0.02, 0.11 |
| No                          | 1.00    | Referent |
| 61-70                       |         |        |
| Yes                         | 0.11    | 0.07, 0.19 |
| No                          | 1.00    | Referent |
| ≥71                         |         |        |
| Yes                         | 0.12    | 0.04, 0.32 |
| No                          | 1.00    | Referent |

Table 4. Effect measure modification of multigene test conductance by age group among patients diagnosed with triple negative breast cancer vs. regular breast cancer\(^a\)

\(^a\): Model was adjusted for year and race. The outcome was whether the patient was diagnosed for triple negative breast cancer vs. regular breast cancer. The primary independent variable was whether the patient received multigene therapy, which is stratified by age group.

**DISCUSSION**

Several important findings were discovered as a result of this analysis. First, trends in TNBC diagnoses typically seen in other studies were also seen in West Virginia. Second, TNBC diagnosis and tumor grade varied by age, which is a novel finding. Third, while multigene testing was infrequently performed among all breast cancer patients, there was an inverse relationship between age and multigene conductance among TNBC patients specifically. These are important findings especially when considering the previous literature indicating delayed diagnoses of breast cancer among West Virginia patients.\(^17\) This generates an imperative to improve early diagnosis, treatment planning, and cancer typing.

In relation to the current literature, the findings were consistent with those of previous nationwide studies. The prevalence of TNBC in West Virginia was 13%, which is similar to the nationwide prevalence of 13%.\(^9\) Similarly, a there was a larger
portion of patients under 40 years old within the TNBC population when compared to the non-TNBC population. Also consistent with the literature was the increased percentage of non-whites in the TNBC population despite a 94% white non-Hispanic population prevalence in West Virginia,\textsuperscript{9,19} and confirmation of TNBC’s aggressive form and increased risk for metastasis. However, the majority of TNBC patients were older adults and there was a significant increased risk for high grade tumor in older patients at time of diagnoses with TNBC.

The novel finding concerning TNBC diagnosis and tumor grade variation by age provides opportunity for future research. The numbers are significant and may be due to biological reasons such as decreased physiologic response with aging, access to care, a feature of the TNBC disease, or some other factor. The finding warrants additional investigation, perhaps using national data.

Multigene testing was not performed frequently, especially in TNBC patients, and the test’s frequency decreased with patient age. The cost, difficulty of coverage for testing, and limitations of many tests in healthcare make this result unsurprising. However, the increasing benefit of genetic and epigenetic research as well as improvements to the multigene test itself may indicate opportunity for change. The data of this project indicates there may be opportunity for improved patient outcomes with future research to identify barriers to its clinical use.

New multigene signature testing provides American Joint Committee on Cancer (AJCC) staging and molecular subtyping, both valuable tools for improving our ability to classify cancer types and generate research data for identifying targeted treatment. Research by Lehman et al discovered from retrospective pretreatment biopsies that prediction regarding neoadjuvant response to therapy was not only possible but indicated the probability that there were both chemotherapeutic sensitive and chemotherapeutic insensitive subtypes in TNBC.\textsuperscript{28} In addition, research from multiple sources of basic science have linked cancer from the breast with the upregulation of a gene, protein, or general pathway.\textsuperscript{29} For example, in 2009, there was documentation of upregulation of hexokinase 2 in breast cancer brain metastasis linked with poor prognosis.\textsuperscript{30} Thus, there is indication that multigene testing could assist evaluation of tumor to aid typing and prognosis for future breast cancer patients. Multigene signature testing alone is not the complete answer to identify targeted treatment, stratify risks, and improve outcomes of clinical applications. However, improved use of this tool in conjunction with other clinical tools and parameters may improve patient stratification for treatment and lead to data for identifying targeted treatments.

**Limitations**

While this study highlighted some important differences between TNBC and non-TNBC in West Virginia, it is not without limitation. One of the inherent limitations of this study was that only a limited number of variables were available for analyses. Some diagnostic variables, such as response to neoadjuvant therapy or risk of
recurrence, contained a large amount of missing data and could not be analyzed. Also, variables which could impact both the diagnoses and prognoses of patients, such as patient obesity status, insurance coverage, patient preference, comorbidities, or access to care, were unavailable, and could be potential confounding factors.

CONCLUSION

This research is broad in its evaluation by use of the entire West Virginia breast cancer registry data. It is unique in its analysis to identify present evidence of TNBC disease in West Virginia and its discussion of testing practice to raise pertinent questions. It is translational in its combination of basic science and clinical application perspective.

Triple negative breast cancer in West Virginia is similar to the nation in its demographic evidence and its aggressive nature. This new finding of TNBC diagnosis and tumor grade variation by age urges future research. While the discussion of multigene signature testing reflects opportunity to evaluate policy and practice for its use. Increased efforts are being made to extend multigene testing to whole genome evaluation of tumors to bolster the information gleaned from tumors. Therefore, increased use of the multigene signature tool may improve our ability to develop biomarkers for early identification of disease, targeted treatment, and response to therapy. Evaluation regarding this finding of exponential increase of high-grade tumor findings with increased age at diagnosis and evaluation of constraints impacting the use of the multigene signature test could be beneficial epidemiologic ventures for future research. This research supports the need for increased focus on tumor evaluation and early diagnosis to improve outcomes for patients.

SUMMARY BOX

What is already known about this topic? Triple negative breast cancer is known to be an aggressive breast cancer subtype with a worse prognosis when compared to other breast cancer types.

What is added by this report? This report is the first evaluation and analysis of TNBC using data representative of all of West Virginia. This report identifies a new finding of TNBC diagnosis and tumor grade variation by age in this Appalachian population. This report also identifies variability in the use of multigene testing in the TNBC population.

What are the implications for future research? Implications for future research are: (1) to identify if this new tumor grade finding is unique to the West Virginia Appalachian population by comparison analysis with nationwide data, and (2) to evaluate policy and practice of multigene signature testing and reporting in West Virginia.
REFERENCES

1. Shah R, Rosso K, Nathanson SD. Pathogenesis, prevention, diagnosis and treatment of breast cancer. World J. Clin. Oncol. 2014;5, 283–98. Doi: 10.5306/wjco.v5.i3.283.

2. Alkabban FM, Ferguson T. Cancer, Breast. in StatPearls 2019.

3. Greenup R, Buchanan A, Lorizio W, et al. Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort. Ann. Surg. Oncol. 2013;20, 3254–8. Doi: 10.1245/s10434-013-3205-1.

4. BreastCancer.Org. Triple-Negative Breast Cancer: Overview, Treatment, and More. Breastcancer.org https://www.breastcancer.org/symptoms/diagnosis/trip_neg (2019).

5. Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Invest. 2011;121, 2750–767. Doi: 10.1172/JCI45014.

6. Dietze EC, Sistrunk C, Miranda-Carboni G, et al. Triple-negative breast cancer in African-American women: disparities versus biology. Nat. Rev. Cancer 2015;15, 248–54. Doi: 10.1038/nrc3896.

7. Lara-Medina F, Perez-Sanchez V, Saavedra-Perez D, et al. Triple-negative breast cancer in Hispanic patients: high prevalence, poor prognosis, and association with menopausal status, body mass index, and parity. Cancer 2011;117, 3658–669. Doi: 10.1002/cncr.25961.

8. Vona-Davis L, Rose, DP, Hazard H, et al. Triple-Negative Breast Cancer and Obesity in a Rural Appalachian Population. Cancer Epidemiol. Prev. Biomark 2008;17, 3319–324. Doi: 10.1158/1055-9965.EPI-08-0544.

9. Plasilova ML, Hayse B, Killelea B, et al. Features of triple-negative breast cancer. Medicine (Baltimore) 2016;95. Doi:10.1097/MD.0000000000004614.

10. Ademuyiwa FO, Tao Y, Luo J, et al. Differences in the mutational landscape of triple-negative breast cancer in African Americans and Caucasians. Breast Cancer Res. Treat. 2017;161, 491–499. Doi: 10.1007/s10549-016-4062-y

11. Anderson K, Thompson P, Wertheim B, et al. Family history of breast and ovarian cancer and triple negative subtype in Hispanic/Latina women. SpringerPlus 2014;3, 727. Doi: 10.1186/2193-1801-3-727.

12. Doepker MP, Holt SD, Durkin MW, et al. Triple-Negative Breast Cancer: A Comparison of Race and Survival. Am. Surg. 2018;84, 881–8.

13. Nahleh Z, Otoukesh S, Mirshahidi HR, et al. Disparities in breast cancer: a multi-institutional comparative analysis focusing on American Hispanics. Cancer Med. 2018;7, 2710–717. Doi: 10.1002/cam4.1509.

14. Newman LA, Kaljee LM. Health Disparities and Triple-Negative Breast Cancer in African American Women: A Review. JAMA Surg. 2017;152, 485–93. Doi: 10.1001/jamasurg.2017.0005.

15. Dietze EC, Chavez TA, Seewaldt VL. Obesity and Triple-Negative Breast Cancer: Disparities, Controversies, and Biology. Am. J. Pathol. 2018;188, 280–90. Doi: 10.1016/j.amjpath.2017.09.018.
16. Siddharth S, Sharma D. Racial Disparity and Triple-Negative Breast Cancer in African-American Women: A Multifaceted Affair between Obesity, Biology, and Socioeconomic Determinants. Cancers 2018;10, Doi: 10.3390/cancers10120514.
17. Abraham J, Flanagan M, Hazard H, et al. Triple-negative breast cancer in West Virginia. W. V. Med. J. 2009;105 Spec No, 54–59.
18. Centers for Disease Control and Prevention. USCS Data Visualizations. Leading cancer cases and deaths, female, 2016.2019 https://gis.cdc.gov/grasp/USCS/DataViz.html.
19. Census, U.S. U.S. Census Bureau QuickFacts: West Virginia; United States. https://www.census.gov/quickfacts/fact/table/WV,US/RHI125218#RHI125218.
20. Bureau, U. C. State Rankings. The United States Census Bureau. 2012 statistical abstract; state rankings https://www.census.gov/library/publications/2011/compendia/statab/131ed/rankings.html (2019).
21. Centers for Disease Control and Prevention. DNPAO Data, Trends and Maps: Explore by Topic | CDC. https://nccd.cdc.gov/dnpao_dtm/rdPage.aspx?rdReport=DNPAO_DTM.ExploreByTopic&islClass=OWS&islTopic=OWS1&go=GO. (2019).
22. Bureau, U. C. State-to-State Migration Flows. The United States Census Bureau https://www.census.gov/data/tables/time-series/demo/geographic-mobility/state-to-state-migration.html.
23. WV OEPS. WV OEPS West Virginia Department of Health and Human Resources, Cancer Registry. https://oeps.wv.gov/cancer/Pages/default.aspx (2019).
24. SEER Registrars. Reporting Guidelines - SEER Registrars. SEER https://seer.cancer.gov/registrars/guidelines.html (2019).
25. Efron B. The Efficiency of Logistic Regression Compared to Normal Discriminant Analysis. J. Am. Stat. Assoc. 1975;70, 892–898.
26. Anders CK, Carey LA. Biology, Metastatic Patterns, and Treatment of Patients with Triple-Negative Breast Cancer. Clin Breast Cancer 2009;9, S73–S81. Doi: 10.3816/CBC.2009.s.008.
27. Zhang Z. Model building strategy for logistic regression: purposeful selection. Ann. Transl. Med. 2016;4. Doi: 10.21037/atm.2016.02.15.
28. Lehmann BD, Jovanovic B, Chen X, et al. Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. PLOS ONE 2016;11, e0157368. Doi:10.1371/journal.pone.0157368.
29. Cynthia X, Ma MD. The Cancer Genome Atlas: Clinical Applications for Breast Cancer. Cancer Network https://www.cancernetwork.com/review-article/cancer-genome-atlas-clinical-applications-breast-cancer (2013).
30. Palmieri D, Fitzgerald D, Shreeve SM, et al. Analyses of Resected Human Brain Metastases of Breast Cancer Reveal the Association between Up-Regulation of Hexokinase 2 and Poor Prognosis. Mol. Cancer Res. 2009;7, 1438–1445. Doi: 10.1158/1541-7786.MCR-09-0234.
31. Vieira AF, Schmitt F. An Update on Breast Cancer Multigene Prognostic Tests—Emergent Clinical Biomarkers. Front. Med. 2018;5. Doi: 10.3389/fmed.2018.00248.